Fred Lublin

64.8k total citations · 11 hit papers
241 papers, 37.1k citations indexed

About

Fred Lublin is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Fred Lublin has authored 241 papers receiving a total of 37.1k indexed citations (citations by other indexed papers that have themselves been cited), including 180 papers in Pathology and Forensic Medicine, 48 papers in Neurology and 47 papers in Rheumatology. Recurrent topics in Fred Lublin's work include Multiple Sclerosis Research Studies (178 papers), Peripheral Neuropathies and Disorders (40 papers) and Rheumatoid Arthritis Research and Therapies (29 papers). Fred Lublin is often cited by papers focused on Multiple Sclerosis Research Studies (178 papers), Peripheral Neuropathies and Disorders (40 papers) and Rheumatoid Arthritis Research and Therapies (29 papers). Fred Lublin collaborates with scholars based in United States, Canada and Switzerland. Fred Lublin's co-authors include Stephen C. Reingold, Chris H. Polman, Jerry S. Wolinsky, Alan J. Thompson, Magnhild Sandberg‐Wollheim, Paul O’Connor, Ludwig Kappos, Massimo Filippi, Brian G. Weinshenker and Eva Havrdová and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Fred Lublin

237 papers receiving 36.0k citations

Hit Papers

Diagnostic criteria for m... 1996 2026 2006 2016 2011 2001 2005 2014 1996 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
    2011 7.6k citations Stephen C. Reingold, Ludwig Kappos et al. profile →
  2. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
    2001 5.4k citations Hans‐Peter Hartung, Fred Lublin et al. profile →
  3. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
    2005 4.0k citations Stephen C. Reingold, Hans‐Peter Hartung et al. profile →
  4. New Multiple Sclerosis Phenotypic Classification
    2014 3.7k citations Fred Lublin profile →
  5. Defining the clinical course of multiple sclerosis
    1996 2.9k citations Fred Lublin, Stephen C. Reingold Neurology profile →
  6. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
    2006 2.4k citations Fred Lublin, Michael Panzara et al. profile →
  7. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
    2006 982 citations Richard A. Rudick, Peter A. Calabresi et al. profile →
  8. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
    2014 664 citations Peter A. Calabresi, Douglas Jeffery et al. profile →
  9. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
    2002 603 citations Fred Lublin et al. Neurology profile →
  10. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
    2016 335 citations Fred Lublin, Bruce Cree et al. profile →
  11. How patients with multiple sclerosis acquire disability
    2022 254 citations Fred Lublin, Dieter A. Häring et al. Brain profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Fred Lublin 30.2k 10.5k 7.7k 6.6k 5.8k 241 37.1k
Xavier Montalbán 29.2k 1.0× 11.8k 1.1× 8.4k 1.1× 6.4k 1.0× 6.4k 1.1× 751 39.1k
Chris H. Polman 37.4k 1.2× 13.1k 1.3× 10.3k 1.3× 7.5k 1.1× 7.9k 1.4× 362 48.9k
Jerry S. Wolinsky 23.4k 0.8× 8.6k 0.8× 6.5k 0.8× 4.0k 0.6× 3.9k 0.7× 243 28.5k
Hans‐Peter Hartung 20.7k 0.7× 14.5k 1.4× 5.9k 0.8× 5.6k 0.9× 8.2k 1.4× 730 43.0k
Paul O’Connor 19.7k 0.7× 6.9k 0.7× 4.8k 0.6× 5.1k 0.8× 4.3k 0.7× 152 25.1k
Brian G. Weinshenker 38.0k 1.3× 23.8k 2.3× 12.1k 1.6× 4.0k 0.6× 6.0k 1.0× 293 47.1k
Ludwig Kappos 40.8k 1.4× 16.0k 1.5× 10.5k 1.4× 9.4k 1.4× 8.2k 1.4× 818 55.7k
George C. Ebers 23.0k 0.8× 7.5k 0.7× 6.8k 0.9× 4.1k 0.6× 7.2k 1.2× 357 31.9k
Claudia F. Lucchinetti 29.0k 1.0× 19.0k 1.8× 8.4k 1.1× 4.1k 0.6× 6.9k 1.2× 231 41.3k
David H. Miller 28.5k 0.9× 11.1k 1.1× 8.2k 1.1× 4.8k 0.7× 3.5k 0.6× 389 39.9k

Countries citing papers authored by Fred Lublin

Since Specialization
Citations

This map shows the geographic impact of Fred Lublin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Lublin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Lublin more than expected).

Fields of papers citing papers by Fred Lublin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Lublin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Lublin. The network helps show where Fred Lublin may publish in the future.

Co-authorship network of co-authors of Fred Lublin

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Lublin. A scholar is included among the top collaborators of Fred Lublin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Lublin. Fred Lublin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bsteh, Gabriel, Nik Krajnc, Patrick Altmann, et al.. (2024). Treating to target in multiple sclerosis: Do we know how to measure whether we hit it?. European Journal of Neurology. 31(12). e16526–e16526. 2 indexed citations
3.
Cutter, Gary, Richard A. Rudick, Carl de Moor, et al.. (2023). Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(2). 3100532663–3100532663. 7 indexed citations
4.
Cutter, Gary, et al.. (2023). The impact of relapse definition and measures of durability on MS clinical trial outcomes. Multiple Sclerosis Journal. 29(4-5). 568–575. 7 indexed citations
5.
Koch, Marcus, Luís Brieva, Jop Mostert, et al.. (2023). Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset. Multiple Sclerosis Journal. 29(14). 1776–1785. 6 indexed citations
6.
Thompson, Alan J., Marcello Moccia, Maria Pia Amato, et al.. (2023). Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community. Multiple Sclerosis Journal. 29(11-12). 1363–1372. 4 indexed citations
7.
Kowalec, Kaarina, Kathryn C. Fitzgerald, Amber Salter, et al.. (2023). Polygenicity of Comorbid Depression in Multiple Sclerosis. Neurology. 101(5). e522–e532. 6 indexed citations
8.
Lublin, Fred, Dieter A. Häring, Habib Ganjgahi, et al.. (2022). How patients with multiple sclerosis acquire disability. Brain. 145(9). 3147–3161. 254 indexed citations breakdown →
9.
Vasileiou, Eleni S., Çharles N. Bernstein, Fred Lublin, et al.. (2022). Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 10(1). 4 indexed citations
10.
Brandstadter, Rachel, Stephen Krieger, Noam Y. Harel, et al.. (2020). Detection of subtle gait disturbance and future fall risk in early multiple sclerosis. Neurology. 94(13). e1395–e1406. 35 indexed citations
11.
Narayana, Ponnada A., Ivan Coronado, Sheeba J. Sujit, et al.. (2019). Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. Radiology. 294(2). 398–404. 80 indexed citations
12.
Fox, Edward, Fred Lublin, Jerry S. Wolinsky, et al.. (2018). Analysis of lymphocyte counts and infection rates with fingolimod in patients with primary progressive multiple sclerosis over the INFORMS trial (P1.387). Neurology. 90(15_supplement). 1 indexed citations
13.
Nelson, Flavia, Christine Lebrun‐Frénay, William Camu, et al.. (2016). Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038). Neurology. 86(16_supplement). 2 indexed citations
14.
15.
Comi, Cristoforo, Timothy R. Vollmer, Fred Lublin, et al.. (2016). Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2 (P3.087). Neurology. 86(16_supplement). 1 indexed citations
16.
Hauser, Stephen L., Gıancarlo Comı, Hans‐Peter Hartung, et al.. (2015). Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201). Neurology. 84(14_supplement). 3 indexed citations
17.
Vollmer, Timothy, Douglas Jeffery, Douglas G. Goodin, et al.. (2013). Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165). Neurology. 80(7_supplement). 7 indexed citations
18.
Lublin, Fred & Stephen C. Reingold. (1996). Defining the clinical course of multiple sclerosis. Neurology. 46(4). 907–911. 2920 indexed citations breakdown →
19.
Lublin, Fred, John N. Whitaker, Benjamin H. Eidelman, et al.. (1996). Management of patients receiving interferon beta-1b for multiple sclerosis. Neurology. 46(1). 12–18. 125 indexed citations
20.
Knobler, Robert L., Jeffrey I. Greenstein, K. P. Johnson, et al.. (1993). Systemic Recombinant Human Interferon-β Treatment of Relapsing–Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up. Journal of Interferon Research. 13(5). 333–340. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xavier Montalbán Breakdown of academic impact, for papers by Chris H. Polman Breakdown of academic impact, for papers by Jerry S. Wolinsky Breakdown of academic impact, for papers by Hans‐Peter Hartung Breakdown of academic impact, for papers by Paul O’Connor Breakdown of academic impact, for papers by Brian G. Weinshenker Breakdown of academic impact, for papers by Ludwig Kappos Breakdown of academic impact, for papers by George C. Ebers Breakdown of academic impact, for papers by Claudia F. Lucchinetti Breakdown of academic impact, for papers by David H. Miller
Rankless by CCL
2026